Autologous renal cell cancer vaccines using heat shock protein-peptide complexes.
Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication.
Aalamian
Maryam
M
Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD 21231, USA.
Fuchs
Ephraim
E
Gupta
Renu
R
Levey
Daniel L
DL
D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006360:Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines; D006360:Heat-Shock Proteins